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1 Introduction 
1.1 Primary Immunodeficiency Diseases 
 
Primary immunodeficiency diseases (PID) are genetically determined disorders affecting the 
functionality of the immune system due to mutations in immune system genes 1. PID have to 
be differentiated from secondary immunodeficiencies, that result as a consequence of 
infections (e.g. human immunodeficiency virus (HIV)), administration of immunosuppressive 
drugs or hematologic diseases (e.g. lymphoma). The diagnosis of PID may be difficult, since 
it may clinically manifest through a broad spectrum of different phenotypes including 
susceptibility to infection but also autoimmune disease, recurrent fever, non-malignant 
lymphoproliferation (splenomegaly and/or lymphadenopathy), or malignant lymphoma 1. 
Currently, more than 350 PID entities have been described 2. PID that lead to life-threatening 
infections very early in life due to dysfunctions of both T and B lymphocytes are classified as 
severe combined immunodeficiencies (SCID) 3. A very rare, but highly lethal form of SCID is 
hepatic veno-occlusive disease with immunodeficiency (VODI), which results by a biallelic 
loss of function mutations in the SP110 gene, encoding for Sp110 protein 1. 
 
1.2 Veno-Occlusive Disease with Immunodeficiency 
 
VODI was first described in 1976 in three families of Lebanese origin. Six children died in the 
first year of life due to severe infections and/or hepatic disease. The children suffered from 
hypogammaglobulinemia, hepatomegaly and various infections, especially pneumocystis 
pneumonia. Besides veno-occlusive disease of the liver, missing germinal centres in the 
lymphoid tissues and a low number of mature plasma cells was reported. The disease was 
reminiscent of a combined immunodeficiency (CID) 4. In addition, one third of the VODI 
patients demonstrated neurological disease including microcephaly, hemiparesis or epilepsy 
5. 30 years later, Roscioli et al. examined six children (3 - 7 months) from five Lebanese 
families suffering from VODI. The patients had no germinal centres in examined lymph nodes 
and liver biopsies showed evidence of veno-occlusion. The patients displayed low 
concentrations of serum immunoglobulins, low memory B cells and tissue plasma cells. 
Peripheral B and T cell numbers were typically within normal range for age. Impaired T cell 
effector function was postulated given the high percentage of severe Pneumocystis jirovecii 
pneumonias 6. Many patients with non-VODI SCID are successfully treated by bone marrow 
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transplantation 7. However, many transplanted VODI patients died due to post-transplant 
complications 5. In particular, the pre-transplant conditioning often fatally aggravated the 
hepatic veno-occlusive disease. Therefore, early substitution with immunoglobulins and 
pneumocystis prophylaxis with Trimethoprim/Sulfamethoxazole (Bactrim) is the treatment of 
choice in patients with VODI 6. However, in 2013 the first VODI patients have been reported 
to be successfully treated with hematopoietic stem cell transplantation 8. Roscioli et al. 
mapped the genetic defect in VODI patients to the gene SP110 encoding for the nuclear 
body protein Sp110. All patients analysed in that study had homozygous loss-of-protein 
expression-mutations in this protein 6.  
 
1.3 The PML Nuclear Body Protein Sp110 
 
Nuclear bodies are divided into five different types, categorised by morphology and location 
9. Sp110 is a member of PML nuclear bodies 10. PML nuclear bodies are thought to be 
important for cell survival, regulation of gene transcription and apoptosis 11 12 13. SP110 is 
located on chromosome 2q37.1 and consists of 2591 base pairs, which corresponds to a 713 
amino acid protein subdivided into several functional domains (see Figure 1b). Until now, 
four Sp110 isoforms have been described (see also Figure 1b). Isoform A encodes for a 
Sp110 protein with a truncated bromodomain (NCBI Reference Sequence: NM_004509.3). 
Isoform B lacks the bromodomain completely (NCBI Reference Sequence: NM_004510.3). 
The full-length protein of Sp110 is encoded by isoform C (NCBI Reference Sequence: 
NM_080424.2). Isoform D encodes for a Sp110 protein with a longer N-terminus but a 
shorter C-terminus compared to the full-length isoform C (NCBI Reference Sequence: 
NM_001185015.1). 
In 1991, autoantibodies against PML- nuclear bodies were reported in sera of patients with 
primary biliary cirrhosis (PBC) 14,15. One year later Szostecki et al. identified the targeted 
nuclear protein as Sp100, named according to its molecular weight of 100 kDa 16. Bloch et al 
identified another PML-nuclear body-autoantigen, named Sp140, that was targeted by sera 
of PBC patients. Sp140 shares many structural similarities with Sp100 and is also 
upregulated upon different stimuli such as IFNs 17. SP110 was cloned in 2000 by Bloch et al. 
into HEp-2 (HeLa derivative) cells and was described as a new member of the Sp100/Sp140 
family 10. Sp110 contains a Sp100 like domain which can also be found in the other family 
members 17 (see also Figure 1b). This domain has been described to be important for 
heterodimerization of the different members 18. The SAND domain, present in all members of 
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the family is delineated to binding chromatin, functions as a transcriptional regulator and is 
often associated with the plant homeodomain (PHD) 19 20. Like the SAND domain, the PHD is 
present in all SP100/SP140 family members 17. The PHD activates gene transcription and 
mediates binding to other nuclear proteins 21. In addition, a bromodomain is highly conserved 
in the SP100/SP140 family and is believed to be important for chromatin rearrangement and 
gene regulation 17 22. A nuclear localization signal (NLS) located in the middle of the protein is 
also shared by all family members 10 23. Since there is the same arrangement of these 
domains in all SP100/SP140 family members, it is likely that SP110 acts as a transcriptional 
activator 10. 
SP110 mRNA is maximally expressed in the peripheral blood, in leukocytes and the spleen. 
Average levels of SP110 mRNA could be found in the thymus, prostate, testis, ovary, small 
intestine and the colon. Low levels of SP110 mRNA are expressed in the heart, brain, 
placenta, lung, liver, skeletal muscle, kidney and the pancreas 10. In summary, Sp110 seems 
to have an expression pattern similar to Sp140 17. In addition, as already shown for the other 
family members, the SP110 mRNA is increased upon IFN stimulation 10.  
Bloch et al. have reported that Sp110 co-localized with Sp100 in PML nuclear bodies and 
that Sp110 depends on Sp140 to access these bodies 10. 
Besides being the causative gene for VODI, Sp110 appears to play a critical role in other 
diseases. Different groups have reported SP110 gene polymorphisms to confer susceptibility 
to or protection from tuberculosis (TB) in different populations such as Indians, Vietnamese 
or Chinese 24 25 26. In contrast, many other studies did not find this correlation 27 28. A murine 
orthologue of human SP110 is lpr1 which has been described to confer innate immune 
protection against tuberculosis 29. Besides the fact that lpr1 is located within a homogenous 
staining region on mouse chromosome 1 and thus highly replicated, homology of murine lpr1 
and human SP110 is very limited and most importantly Ipr1-deficient mice do not display a 
VODI-like phenotype 29.  
Sp110 is also differentially expressed in autoimmune diseases like systemic lupus (SLE) or 
malignant lymphoproliferative diseases 30 31 32. The mechanism of how absent Sp110 leads 
to the clinical and immunological features of VODI remains unclear. 
 
1.4 Type I interferons (IFN I) 
 
Type I interferons (IFN I), comprising interferon α, interferon β and other related proteins 
were identified as anti-viral cytokines by transcriptionally activating genes called interferon-
Introduction  8 
 
stimulated genes (ISG) which interfere with viral replication 33 34 35 36. In addition, they have 
immune-modulatory functions 33 37. All IFN I bind to the same receptor, IFNAR, consisting of 
IFNAR1/IFNAR2 heterodimers 38 39.  
IFNAR dimerization of the receptors enables binding/activation of Janus kinase 1 (JAK1) and 
tyrosine kinase 2 (TYK2). These kinases subsequently phosphorylate IFNAR resulting in a 
recruitment of signal transducers and activators of transcription (STAT). In total there are 
three predominant STAT complexes formed upon the phosphorylation of the receptor. The 
phosphorylation of the STAT multicomplex promotes the activation of IFN-stimulated genes 
(ISG) 40. Until now nearly 1000 ISG have been identified and Sp110 is one of them 10. 
PID that are characterized by chronic and inadequate overproduction of ISG are called 
interferonopathies 1. These diseases are caused by gain of function mutations in genes 
controlling ISG formation and associated with neuro-immunologic and autoimmune diseases 
with a wide clinical spectrum 42. Polygenic human systemic autoimmune diseases such as 
systemic lupus erythematosus (SLE) or Sjogren`s syndrome are also linked to elevated ISG 
43. On the other hand, loss of function mutations in IFN-I or its receptor are linked to severe 
infections 44. 
 
1.5 T cell apoptosis 
 
To guarantee T cell homeostasis, pathogen-specific T cells, following rapid clonal expansion 
upon infection, have to undergo regulated cell death (apoptosis) after clearance of the 
pathogen 45. Furthermore, T cell apoptosis at the peak of T cell reactivity is required to avoid 
immunopathologic damage of the host 46. Despite other types of regulated cell death, two 
main pathways of apoptosis induction have been characterized 47. 
Extrinsic apoptosis is induced by ligand binding to death receptors of the tumor necrosis 
factor (TNF) superfamily 48. These receptor have in common that all members share a 
cytoplasmic death domain 49. The most prominent ligands for these receptors are FasL, 
TRAIL and TNF-α 50 51 52. The activation of the receptors (CD95, TRAIL receptors and 
TNFRI) leads, by engaging the death domains to the formation of the multicomplex death-
inducing signalling complexes (DISC). These complexes drive the auto-catalytic activation of 
caspase-8 53 54. Subsequently, activated caspase-8 proteolytically activates the effector 
caspase-3 and -7 in thymocytes and mature lymphocytes 55.  
Intrinsic apoptosis is triggered by different stimuli like toxins, hypoxia or radiation 56. Central 
to intrinsic apoptosis induction is irreversible mitochondrial outer membrane 
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permeabilization (MOMP) 57. MOMP is executed by the proapoptotic BCL-2 family members 
BAK, BOK and BAX 58 59. These proteins are responsible for pore formation in the outer 
membrane of the mitochondria (OMM) 60 58. BAK and BAX are activated by several 
proapoptotic BH3-only proteins (containing only one BH3 domain), including PUMA, NOXA 
and BIM whose expression is primarily controlled on a transcriptional level 61 62 63 64 65. These 
proapoptotic BH3-only proteins interact with BAK and BAX, leading to their dimerization and 
to MOMP 66 63 67 68. MOMP can be prevented by antiapoptotic proteins of the BCL-2 family 
such as BCL2, BCL-XL, MCL1, BCL-W or BFL-1 58 69. These proteins which all express four 
BH3 domains are located in the OMM and inhibit the oligomerization of BAK and BAX or 
directly prevent the process of pore forming 70 58.  
Mitochondrial outer membrane permeabilization leads to a release of apoptotic factors out 
of the mitochondrial intermembrane space 57 71. One essential proapoptotic factor is 
cytochrome C 72. Released cytochrome C binds the cytosolic apoptotic peptidase activation 
factor 1 (APAF1) allowing recruitment of pro-caspase-9. Subsequently, a protein 
multicomplex, the apoptosome is formed and proteolytically activates the initiator caspase-9 
73. Matured caspase-9 subsequently activates the effector caspase-3 and -7 74 75. 
Both, the intrinsic and extrinsic pathway of T cell apoptosis finally leads to typical features of 
apoptosis like DNA fragmentation, phosphatidylserine exposure and formation of apoptotic 
bodies 76 41 77 78. 
 
1.6 Pneumocystis jirovecii infection  
 
Pneumocystis jirovecii, formerly known as Pneumocystis carinii, is a pathogen which belongs 
to the family of fungi 79 80. It is transmitted via respiratory droplets and infects the airways of 
individuals 81. Pneumocystis infection may cause a severe pneumonia in patients who are 
immunosuppressed such as patients with HIV, patients treated with systemic steroids or 
other immunosuppressants, e.g. after organ transplantation 82. Pneumocystis does not 
typically lead to severe disease in patients with absent B cells 83, implying that T cell 
responses rather than antibodies are essential in the anti-pneumocystis immune response. In 
immunocompetent individuals, pneumocystis induces a self-limited airway infection or is 
cleared without symptoms 83. It has been demonstrated that the adaptive T cell response 
induces immunopathologic lung damage following pneumocystis infection. In a murine 
model, depletion of T cells was even superior to antibiotic treatment to prevent severe lung 
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damage 84. Also in human pneumocystis pneumonia immunosuppression induced by adjunct 
steroids in addition to antibiotics have resulted in better outcomes 85.  
In VODI patients, early immunoglobulin supplementation by intravenous immunoglobulins 
(IVIG) and Pneumocystis jirovecii prophylaxis by Trimethoprim/Sulfamethoxazole (Bactrim) 
improves the course of disease 6 86. 
 
In this thesis we addressed the question how absent Sp110 alters T cell function. 
Specifically, our aim was to analyze whether absent Sp110 might alter activation induced T 
cell apoptosis which might impact on T cell driven immunopathology following pneumocystis 
infection. 
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2 Methods 
2.1 Isolation of PBMC/generation of T cell blasts 
 
For generation of primary T cell blasts from healthy individuals, EDTA blood tubes or buffy 
coats were received from the blood donation centre Basel following informed consent. EDTA 
blood from VODI patients was obtained following informed consent according to protocol 04-
09-113R approved by the Boston Children’s Hospital Institutional Review Board. ETDA-blood 
was mixed 1 to 1 with phosphate buffered saline (PBS) (Sigma-Aldrich). The diluted EDTA 
blood was then layered over a gradient of lymphoprep (Axis-Shield) in a 50 ml Falcon tube. 
Subsequently the tube was centrifuged for 20 min at 1800 rpm using the settings 
acceleration 4 and brake 1. By centrifugation of the blood through the lymphoprep gradient, 
different cell fractions were separated. From top to bottom the first layer contained the 
plasma, followed by a layer which contained the peripheral blood mononuclear cells (PBMC) 
and platelets. The next layer consisted of the lymphoprep reagent. Directly on top of the 
erythrocytes there was a small whitish layer containing the granulocytes. Erythrocytes were 
located at the bottom of the tube following centrifugation. PBMC were isolated by careful 
pipetting and washed with 50 ml PBS. Afterwards the solution was centrifuged for 5 minutes 
at 1800 rpm. If the cell pellet contained too many erythrocytes a lysis step using an 
erythrocyte lysis buffer (Qiagen) was performed. Therefore the pellet was re-suspended in 1 
ml of lysis buffer for 5 minutes at room temperature (RT). Afterwards cells were washed with 
50 ml PBS and centrifuged. In the next step the cell pellet was resuspended in RPMI-
medium and the concentration of the cells was determined by an EVE Automatic cell counter 
(NanoEnTek). Subsequently, 3 x 106 cells/ml PBMC were seeded on a 96-well U-bottom 
plate. To generate T cell blasts PBMC were stimulated with 5 µg/ml PHA (Sigma-Aldrich) and 
IL-2 (300 IU/ml, Novartis). Every 4-7 days, T cell blasts were expanded 1:1 in new medium 
containing fresh IL-2. While PBMC derived T cells normally had more CD4+ T cells compared 
to CD8+ T cells, the CD4+/CD8+ T cell ratio was typically < 1 in expanded T cell blasts (see 
Figure 3). 
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2.2 Jurkat T cells 
 
Jurkat T cells were first isolated in 1977 form a patient with T cell leukemia 87. In this thesis 
all Jurkat T cell based experiments were performed using the Jurkat clone E6.1 as parental 
Jurkat T cell line (SP110wt).  
 
2.3 Cell culture 
 
Jurkat T cells and primary PBMC-derived T cell blasts were cultured in RPMI-medium 
(Sigma-Aldrich) containing 100 U/ml Penicillin-Streptomycin (Gibco), 5 ml of 100 x MEM 
Non-Essential Amino Acids Solution (Gibco) and 5 ml of 100 x GlutaMAX (Gibco) per 500 ml 
RPMI-medium. Full medium contained 10% fetal calf serum (FCS, Gibco). T cells were 
cultured using the following settings: 5% CO2, 18% O2 and 37°C. Before every experiment, 
cell viability and cell numbers were controlled using an EVE Automatic cell counter 
(NanoEnTek). 
 
2.4 Reagents for cell stimulation  
 
Primary PBMC derived T cell blasts or Jurkat T cells were stimulated with different reagents 
to induce cell activation and related apoptosis. T cells were transferred to a 96-well U-bottom 
plate at 3 x 106 cells/ml and stimulated with reagents/inhibitors as listed in Table 1. Unless 
otherwise stated, primary T cell blasts or Jurkat T cells were stimulated for four hours in the 
incubator prior to analysis of T cell apoptosis. Specific inhibitors of signalling pathways were 
used at the concentrations listed in Table 1 and were added 30 minutes prior to cellular 
stimulation. 
Table 1 Reagents and inhibitors used for stimulation of primary T cells and Jurkat T 
cells 
Reagents Final conc. Company 
PMA 5 ng/ml Sigma-Aldrich 
Anti-human CD95/Fas (EOS9.1) 5 µg/ml Biolegend 
Interferon α-2a 3000 IE/ml Roche 
Inhibitors   
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C Jun N terminal kinase 
inhibitor (SP600125) 
100 µM Sigma-Aldrich 
panSTAT inhibitor (SH-4-54)  100 nM Sigma-Aldrich 
JAK1/2 inhibitor Ruxolitinib  10 µM Sigma-Aldrich 
 
2.5 Ultraviolet-light irradiation  
 
To induce apoptosis by UV-light, primary T cell blasts or Jurkat T cells were irradiated with 
UV-C light (254 nm) at doses ranging from 50 J/m2 – 200 J/m2. The irradiation was done in a 
Stratalinker UV Crosslinker 1800 UV-chamber (Stratagene).  
 
2.6 Flow cytometric analysis for intracellular/nuclear proteins or 
protein phosphorylation 
 
To determine intracellular protein expression or intracellular protein phosphorylation, primary 
T cell blasts or Jurkat T cells were fixed at room temperature (RT) for 20 min with Fix/Perm 
buffer (BD Biosciences). After fixation and washing in 2% FCS/PBS, cells were 
permeabilized with Perm III Buffer (BD Biosciences) at 4°C for 30 min. The primary 
(unlabeled) antibody was diluted 1:100 in 2% FCS/PBS and added to the cells for 45 min at 
RT (Table 2). Non-specific isotype control or normal rabbit IgG served as non-specific 
staining controls. Following washing in 2% FCS/PBS, the cells were incubated for 30 min at 
RT with Alexa Fluor 488/647 – conjugated secondary antibodies directed against the primary 
antibody (e.g. anti rabbit IgG, Jackson ImmunoResearch) diluted 1:100 in 2% FCS/PBS for 
45 minutes. Protein expression or protein phosphorylation was determined on a CytoFLEX 
(Beckman Coulter) or BD Accuri C6 (BD Biosciences) and the analysis was performed using 
FlowJo software (FlowJo LLC). 
Table 2 Primary and secondary antibodies used to detect intracellular proteins or 
protein phosphorylation 
Primary antibodies Final conc. (µg/ml) Company 
Sp110 rabbit polyclonal IgG  1.6  Proteintech 
p-c-Jun (Ser73) rabbit monoclonal  
IgG  
0.35  Cell Signaling  
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pSTAT1 (Tyr701) (58D6) rabbit 
monoclonal IgG  
0.45 Cell Signaling  
pSTAT3 (Tyr705) (D3A7) rabbit 
monoclonal IgG  
0.45 Cell Signaling 
Rabbit control polyclonal IgG  Adjusted Proteintech 
Rabbit isotype control monoclonal IgG 
(DA1E) 
Adjusted Cell Signaling 
Secondary antibody   
Alexa Fluor 488 Fab2 Fragment 
goat anti-rabbit IgG 
0.75 Jackson 
ImmunoResearch  
Alexa Fluor 647 Fab2 Fragment 
goat anti-rabbit IgG 
0.75 Jackson 
ImmunoResearch 
 
2.7 Flow cytometry assay to detect cell-surface proteins 
 
To assess the expression of surface proteins by flow cytometry, primary T cell blasts or 
Jurkat T cells were washed in 2% FCS/PBS and stained with 1:100 diluted fluorochrome-
labeled antibodies for 30 min at room temperature (Table 3). To confirm the specificity of the 
staining cellular aliquots were stained with a respective isotype control. Subsequently, cells 
were washed in 2% FCS/PBS. The protein expression was measured afterwards on a 
CytoFLEX (Beckman Coulter) or a BD Accuri C6 (BD Biosciences). Analysis of the data was 
performed using FlowJo software (FlowJo LLC). 
Table 3 Primary antibodies for cell surface staining  
Antigen (clone) Fluorochrome Conc. (µg/ml) Company 
AnnexinV FITC, APC 0.5 Biolegend 
CD3 (UCHT1) PE, PE/Cy7, APC 0.5 Biolegend 
CD4 (SK3) PE/Cy7 0.5 Biolegend 
CD8 (SK1) PE, PE/Cy7 0.5 Biolegend 
CD27 (O323) FITC, APC 0.4 Biolegend 
CD45RO (UCHL1) PE 0.1 Biolegend 
Isotype Ctrl FITC, PE, PE/Cy7, APC Adjusted Biolegend 
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2.8 Detection of apoptosis by flow cytometry 
 
Primary T cell blasts or Jurkat T cells, either left unstimulated or treated with the indicated 
inducers of apoptosis (see Table 1), were cultured for four hours. Afterwards, cells were 
washed twice with AnnexinV Binding Buffer (Biolegend) and stained with 1 µg/ml FITC/APC-
labeled AnnexinV, 1:100 diluted in AnnexinV Binding Buffer, for 30 min at RT to detect 
apoptosis-associated phosphatidylserine exposed at the cell surface. Subsequently, the cells 
were washed again with AnnexinV Binding Buffer. Apoptotic T cells displaying binding of 
fluorochrome labelled AnnexinV were enumerated using a CytoFLEX flow cytometer 
(Beckman Coulter) and the data were analyzed with FlowJo software (FlowJo LLC). 
 
2.9 Flow cytometric analysis of caspase-9 activity 
 
To assess caspase-9 activity by flow-cytometry, 5 x 105 cells/sample primary T cell blasts 
were stimulated with different stimuli (see Table 1). Four hours later, cells were incubated for 
additional 30 minutes in medium containing fluorescently labelled caspase-9 inhibitor FAM-
FLICA (ImmunoChemistry Technologies). The staining procedure was performed according 
to the manufacturer`s protocol. Caspase-9 activity was measured on a BD Accuri C6 (BD 
Biosciences) and subsequently analyzed with FlowJo software (FlowJo LLC).  
 
2.10 siRNA knockdown of specific genes in Jurkat T cells and 
primary T cell blasts 
 
Transient transfection with siRNA was performed with the AMAXA Nucleofection Kit T cell 
(Lonza Group Ltd.) for transfecting primary T cell blasts or AMAXA Nucleofection Kit V 
(Lonza Group Ltd.) for Jurkat T cells. 5 x 106 cells/sample primary T cell blasts or 2 x 106 
cells/sample Jurkat T cells were transfected by electroporation according to the 
manufacturer’s protocol. The following SP110 specific and non-specific siRNAs were used: 
500 nM Flexi Tube siRNA Hs SP110 1/4/5/6/9/10 and 11 (Qiagen) 
500 nM AllStars Neg. Control siRNA (Qiagen) 
After electroporation the cells were transferred into pre-warmed RPMI medium and rested for 
24 hours at 37°C. Gene knockdown efficacy was tested afterwards by real-time PCR or by 
measurement of Sp110 protein expression by flow cytometry. Prior to apoptosis induction 
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using the stimuli listed in Table 1, enrichment for live cells using a magnetic bead-based 
dead cell removal Kit (Miltenyi Biotec) and LS Columns (Miltenyi Biotec) was executed. The 
procedure was done according to the manufacturer`s protocol.  
 
2.11 Generation of SP110 knockout Jurkat T cells 
 
To knockout SP110 in Jurkat T cells, 2 x 106 cells/sample were transfected by 
electroporation with a predesigned SP110 CRISPR/Cas9 Ko plasmid mix (Santa Cruz 
Biotechnology Inc.) containing three different SP110 specific sgRNAs, the Cas9 
endonuclease and P2A-EGFP. 24 hours later, cells were sorted for GFP expression on an 
Aria III cytometer (BD Biosciences) and single cells were plated on a 96-well U-bottom plate. 
After 2 - 3 weeks of single cell clone-expansion, cDNA was generated from individual clones 
and a specific PCR was performed, amplifying a 461 bp SP110 fragment, covering the region 
that was targeted by the guide RNA. The amplified PCR product was run on a 1.5 % agarose 
gel, cut, isolated and sequenced by Sanger sequencing to detect insertions/deletions (Table 
4). To confirm that SP110 knockout Jurkat T cell clones indeed lacked Sp110 protein, a 
Sp110 specific flow cytometry staining was performed (Figure 2). The detailed molecular 
analysis of the SP110ko Jurkat T cell clone has been published 88. 
Table 4 CRISPR/Cas9 derived T cell Jurkat clones 
Clone Modification Sp110 protein expression 
SP110ko Insertion of 8 bp Knockout 
SP110wt None Basic expression 
 
2.12 Lentiviral transduction 
 
For Sp110 overexpression in Jurkat T cells, 5 x 104 cells/sample SP110ko Jurkat T cells were 
plated on a 12- well plate and incubated with different volumes of the Sp110 overexpressing 
lentivirus provided by Donald Bloch, Massachusetts General Hospital, Boston, USA. Two 
different lentiviruses contained transgenes either encoding for full length Sp110 (isoform C) 
or red fluorescence protein (RFP) as a transduction control. In addition both viruses encoded 
for a green fluorescent protein (GFP) (Table 5). For transduction, the lentivirus-containing 
supernatant was thawed on ice and a transduction-solution was prepared. 957 µl RPMI-
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medium (Sigma-Aldrich) was mixed with 8 µl Polybrene (1mg/ml, Sigma-Aldrich). 
Subsequently 35 µl of the lentiviral supernatant were added to the solution. Subsequently, 
SP110ko Jurkat T cells were incubated with the mix. Cells were then centrifuged for 90 min at 
800g and incubated over night at 37°C. On the following morning, the lentiviral supernatant 
was removed and fresh medium was added. One week after transduction, cells with high 
GFP expression were sorted on an Aria III cytometer (BD Biosciences) and single cells were 
plated on a 96-well U-bottom plate. Sp110 expression was detected on individual clones by 
flow cytometry and SP110hi expressing clones were propagated. Jurkat T cell clones with 
high red fluorescence (SP110ko) served as a transduction control. 
Table 5 Lentiviral transduced Jurkat T cell clones 
Clone Transduced constructs Sp110 protein expression 
SP110ko RFP + GFP Knockout 
SP110hi SP110 + GFP Overexpression 
 
2.13 Protein quantification by western blot 
 
To detect protein expression by western blot, 2 x 106 cells/sample Jurkat T cells were 
washed in PBS and mixed with protein lysis buffer. This buffer contains 50 mM HEPES pH 
7.9, 250 mM NaCl, 20 mM glycerophosphate, 5 mM Na2-4-nitrophenylphosphate, 1 mM 
EDTA-Na2, 1 mM Na-orthovanadate, 0.5% (v/v) Nonidet P-40, 10% (v/v) glycerol, 5 mM DTT 
and protease inhibitors (Sigma-Aldrich and Roche). Subsequently, the suspension was 
shaken for 20 min at 4°C. Afterwards, the solution was sonicated using a W-375 sonicator/ 
cell disruptor (Heat Systems-Ultrasonics Inc.). To remove the non-digestible part of the cells 
the solution was centrifuged at 12.000 rpm for 15 min at 4°C. The protein concentration of 
the cell lysate was determined by a Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). 
The procedure was done according to the manufacturer`s protocol. 
For western blotting, 20 µg protein/sample were diluted in 2 x Laemmli buffer (Bio-Rad 
Laboratories) and loaded on a 4-15% Mini-PROTEAN TGX 1-D polyacrylamide gel (Bio-Rad 
Laboratories). The settings for the separation were 100 V/ 0.2 A for 1.5 hours. Following 
electrophoresis, gels were transferred onto a 0.2 µm nitrocellulose Trans-Blot Turbo 
membrane (Bio-Rad Laboratories). To prevent unspecific binding, the blot was washed with 
TBS/T with 5% BSA (Sigma-Aldrich) for one hour at RT. The membrane was then incubated 
with the indicated dilutions of primary antibody diluted in TBS/T rotating over night at 4°C 
(Table 6). On the next morning, the blot was incubated with the indicated dilutions of the 
Methods  18 
 
fluorochrome-coupled secondary antibodies diluted in TBS/T shaking for one hour at 37°C 
and subsequently blot-fluorescence was visualized using the ODYSSEY CLx (LI-COR).  
Table 6 Primary and secondary antibodies for Western blotting 
Primary antibody Final conc. (ng/ml) Company 
Caspase-9 rabbit IgG monoclonal 42 Cell Signaling 
Secondary antibody Final conc. (ng/ml) Company 
IRDye 800 CW goat anti-rabbit IgG 
(H+L) 
100 Licor 
 
2.14 DNA isolation  
 
For DNA isolation, 5 x 106 cells/sample primary T cell blasts or Jurkat T cells were pelleted 
by centrifugation. DNA isolation from cell pellets was done using a QIAmp DNA Blood Mini 
Kit (Qiagen). The isolation was done in accordance to the manufacturer`s protocol. Following 
purification, the DNA concentration was determined using a NanoDrop (Thermo Fisher 
Scientific). 
 
2.15 Endpoint PCR 
 
The amplification of the template DNA was performed using the GoTaq G2 DNA Polymerase 
(Promega) in the presence of SP110 isoform specific primer pairs (Table 7). The primer 
concentration was set to 0.5 µM.  
Table 7 Primer used for endpoint PCR 
Gene Sequence 
forward/reverse 
Company 
SP110 isoform A  TCTAAGACCCTGGAGAGGCA 
ATGGTTGCGAAACATCAGGC 
Microsynth 
SP110 isoform B  TTTGCTCTGTCCTCCAAGAA 
TCCCCATCCCAAATTAACTATGC 
Microsynth 
SP110 isoform C  TGAAGGCCTACTGTCATCCA 
ACCAGGTCCAACCACATTGC 
Microsynth 
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SP110 isoform D  TTGCCTAACTAGCTGACGTG 
ATGGCTCTTGTCATGGTGAACA 
Microsynth 
 
The PCR was performed on a TProfessional TRIO PCR Thermocycler (Core Life Sciences) 
and according to the manufacturer`s protocol. The specific program for the reactions was: 
Table 8 Settings for endpoint PCR 
Temperature (°C) Time (sec) Cycles 
95 120 1 
95 20  
38 62 20 
72 45 
72 300 1 
 
PCR products were separated and visualized on a 1.5 % agarose gel (Sigma-Aldrich) using 
a Molecular Imager Gel Doc XR+ (Bio-Rad).  
 
2.16 RNA isolation and cDNA synthesis 
 
5 x 106 primary T cell blasts or Jurkat T cells were lysed in Trizol (Thermo Fisher Scientific) 
and subsequently mixed with chloroform (Sigma-Aldrich). The isolation was performed using 
the QIAamp RNA Blood Mini Kit (Qiagen) according to the manufacturer`s protocol. The 
concentration of the RNA was determined by a NanoDrop (Thermo Fisher Scientific). RNA 
samples were treated with DNase I – Amplification Grade Kit (Sigma-Aldrich) to eliminate 
DNA. For cDNA synthesis, 100 ng/µl - 1 µg/µl RNA was mixed with random primer 
(Promega) and placed in a TProfessional TRIO PCR Thermocycler (Core Life Sciences) at 
70°C for 5 min for primer annealing. The reverse transcription polymerase chain reaction was 
performed according to the companies protocol “GoScript Reverse Transcription System”. 
 
2.17 Analysis of mRNA expression by real-time PCR 
 
Gene-specific mRNA expression was quantified by real-time PCR. Most gene-specific primer 
(listed in Table 9) were designed using the NCBI Gene Databank/Primer-BLAST and 
synthesized by the company Microsynth. SP110 and IFNγ mRNA specific real-time PCR 
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primer were purchased (Qiagen). Real-time PCR was performed with the GoTaq qPCR 
Master Mix (Promega) and primer concentrations set to 0.5 µM.  
Table 9 Primer used for real-time PCR analysis 
Gene Sequence 
Forward/reverse 
Company 
SP110  n/a Qiagen 
18s GCTTAATTTGACTCAACACGGGA 
AGCTATCAATCTGTCAATCCTGCT 
Microsynth 
IPO8 TCCTTGGCCTAAAGCAGGTC 
ACTGCATTGCTTGAGCAGTTA 
Microsynth 
Actin CAACCGCGAGAAGATGACCC 
AGAGGCGTACAGGGATAGCA 
Microsynth 
GAPDH GGTCACCAGGGCTGCTTTTA 
TTCCCGTTCTCAGCCTTGAC 
Microsynth 
 
PUMA GAAATTTGGCATGGGGTCTGC 
GGGGAGCTGCCCTCCT 
Microsynth 
BIM CTCTCGGACTGAGAAACGCA 
CGCAGGCTGCAATTGTCTAC 
Microsynth 
NOXA AGTTGGAGGCTGAGGTTCCC 
TTGAGTAGCACACTCGACTTC 
Microsynth 
IFNγ n/a Qiagen 
TNFα GCCTCTTCTCCTTCCTGATCG 
AGAGGGCTGATTAGAGAGAGG 
Microsynth 
 
The PCR was done in a TProfessional TRIO PCR Thermocycler (Core Life Sciences) with 
the following settings:  
Table 10 Settings for real-time PCR 
Temperature (°C) Time (sec) Cycles 
50 120 1 
95 600 1 
95 
60 
15 
60 
40 
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Unless otherwise stated, cDNA expression of the gene of interest was always normalized to 
the house keeping genes 18s and/or IPO8. The results were calculated using the method 
designed by Michael W. Pfaffl using the cycle numbers of specific gene detection 89. 
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3 Results 
3.1 Application of molecular tools to measure T cell intrinsic Sp110 
protein quantity and to functionally study T cells with Sp110 
over- vs. non-expression 
 
The diagnosis of Sp110 deficiency has been challenging partly due to the fact that 
quantification of Sp110 protein has only been possible using time-consuming techniques 
(e.g. immunofluorescence microscopy of EBV immortalized B cell lines) 86. In addition, our 
own experiments demonstrated that many commercially available Sp110-specific antibodies, 
due to non-specific binding, cannot be used to distinguish cells expressing vs. non-
expressing Sp110 protein (data not shown).  
In a recently published report by Marquardsen/Baldin et al. in the Journal of Clinical 
Immunology, we have established an easy to perform, rapid flow cytometric test to quantify 
Sp110 protein in human T lymphocytes 88. This flow cytometric test, using a commercially 
available polyclonal IgG rabbit anti-serum against Sp110, has been validated for its ability to 
diagnose Sp110 deficiency in five patients suffering from VODI. A reprint of this manuscript is 
attached to the PhD Thesis. 
The clinical and molecular characteristics of the patients with Sp110 deficiency (VODI) that 
were enrolled for the subsequent studies discussed in this PhD thesis are summarized in 
Table 11.  
 
Table 8 Clinical and molecular characteristics of patients with Sp110 deficiency 
Pat. 
nr. 
SP110 
mutation 
Gender Age at 
diagnosis 
Current 
age 
Clinical 
complications 
Treat- 
ment 
1 642delC/ 
642delC 
 
Female 3 months 8 years Pneumocystis 
pneumonia, liver 
fibrosis 
IVIG, 
Bactrim 
 
2 642delC/ 
642delC 
 
Female 4 months 5 years Recurrent 
pulmonary and 
intestinal infections, 
subacute 
pancreatitis 
IVIG, 
Bactrim 
 
3 78_79delinsAT/
78_79delinsAT 
 
Female 3 years 11 years Pneumocystis 
pneumonia, veno-
occlusive disease 
of the liver 
IVIG, 
Bactrim 
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4 T80C/T80C 
 
Male 9 months 10 years Liver fibrosis, 
recurrent sinusitis, 
thrombocytopenia 
IVIG, 
Bactrim 
 
IVIG: intravenous immunoglobulin substitution 
 
Figure 1a representatively depicts Sp110 flow cytometric analysis of peripheral blood 
derived T cells of a patient with VODI (patient nr. 3), two clinically healthy siblings carrying a 
disease-causing SP110 mutation heterozygously and a non-related control. The results 
indicate that the flow-based assay to quantify Sp110 expression in T cells is not only able to 
identify the patient, but also the clinically healthy carriers of disease-causing SP110 
mutations (intermediate Sp110 expression). 
Sp110 protein, encoded by 19 exons, contains different functional domains consisting of 
domains accountable for interactions with other proteins (SP110 like domain) or with DNA 
(SAND domain, PHD domain and bromodomain) 10. Besides the full-length SP110 isoform 
(isoform C), other isoforms have been described, encoding for truncated Sp110 proteins 
lacking part of the bromodomain (isoform A), completely lacking the bromodomain (isoform 
B) or having a different C-terminus (isoform D) (NCBI gene 2018) (Figure 1b, adapted from 
90). Endpoint PCR specific for the four SP110 isoforms were performed on T cell blast 
derived cDNA from a healthy individual or VODI patient nr.1 demonstrating that all SP110 
isoforms are expressed in primary human T cell blasts. Since the homozygous 642delC 
SP110 mutation in VODI patient nr.1 does not lead to complete loss of SP110 mRNA 
expression, all four mRNA isoforms were also detectable in the VODI patient-derived T cell 
blasts (Figure 1c). 
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Figure 1 
a) Sp110 protein expression in PBMC derived T cell blasts was assessed by flow cytometry in a VODI 
patient (SP110-/-, patient nr. 3), two siblings carrying a disease-causing Sp110 mutation 
heterozygously (SP110+/-) and a non-related control (SP110+/+). Flow cytometric analysis of CD3-
fluorescence or fluorescence following staining with normal rabbit IgG is depicted as a control. b) 
Schematic representation of the SP110 gene. Lengths of the different isoforms are indicated. c) cDNA 
was generated from T cell blasts derived from a healthy individual or a VODI patient (patient nr. 1). 
Endpoint PCR analysis using specific primer amplifying either SP110 isoform A and C (left lanes) or 
SP110 isoforms B and D (right lanes) was performed and the different bands were visualized after 
agarose gel separation.  
 
We next successfully generated a Jurkat T cell line lacking Sp110 expression (SP110ko) 
using the CRISPR/Cas9 system (generation described in detail in 88). Using the SP110ko 
Jurkat T cell line, we at next generated a Jurkat T cell line that stably overexpressed Sp110 
(SP110hi). To do this, we lentivirally transduced the SP110ko Jurkat T cell line with two 
different lentiviruses, either encoding for a SP110 plus GFP (SP110hi) or, as a transduction 
control, encoding for a RFP plus GFP (SP110ko). SP110 mRNA expression as tested by real-
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time PCR was 20-fold higher in the SP110hi and 3.5-fold higher in SP110wt Jurkat T cells 
compared to SP110 mRNA expression in SP110ko Jurkat T cells (Figure 2a). Flow 
cytometric analysis of Sp110 expression revealed that, indeed, SP110hi Jurkat T cells 
overexpressed Sp110 protein, while baseline Sp110 expression was observed in SP110wt 
Jurkat T cells. In contrast, SP110ko Jurkat T cells did not express Sp110. Staining with 
normal rabbit IgG was served as flow-cytometric staining control (Figure 2b).  
 
 
 
Figure 2 
a+b) SP110ko, SP110wt and SP110hi Jurkat T cells were analyzed for SP110/Sp110 expression. a) 
SP110 mRNA expression was measured by real-time PCR in SP110ko, SP110wt and SP110hi 
(expression in the latter was set to 1). b) Sp110 protein levels were measured by flow cytometry using 
Sp110-specific rabbit antiserum or normal rabbit IgG as a control (SP110ko Jurkat T cells, light grey 
histograms; SP110wt Jurkat T cells, dark grey histograms and SP110hi Jurkat T cells, black 
histograms).  
 
3.2 Analysis of T cell intrinsic roles of Sp110 that might support 
susceptibility to pneumocystis-induced disease in VODI 
patients  
 
Pneumocystis is a typical opportunistic infection in patients chronically infected with HIV 
linked to the degree of CD4+ T cell lymphopenia 91. Although peripheral T cell numbers in 
VODI patients have been described to be within reference ranges for age 6, we used our 
cohort of VODI patients to determine the CD4+/CD8+ T cell ratio in PBMC and T cell blasts. 
As shown in Figure 3a, the CD4+/CD8+ T cell ratio was unaltered in PBMC from VODI 
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patients compared to healthy control individuals. There was no relative CD4+ T cell 
lymphopenia that might have explained the susceptibility to pneumocystis. Also, following in 
vitro generation of T cell blasts derived from PBMC using PHA and IL-2 (see methods), the 
majority of T cell blasts were CD8+ T cells, both in T cell blasts generated from VODI patients 
and from healthy control individuals (Figure 3b). Thus, we did not find evidence of 
differences in T cell subpopulations in VODI patients compared to healthy control individuals. 
 
 
 
 
Figure 3 
a+b) PBMC derived T cells or T cell blasts of VODI patients or healthy control individuals were stained 
for proteins defining the indicated T cell subsets and analyzed by flow cytometry. Statistics were 
performed with an unpaired T-test, ns = p>0,05; * = p<0,05; ** = p<0,005. Mean and standard 
deviation are depicted. 
 
3.2.1 Sp110 orchestrates activation-induced T cell apoptosis 
 
It has been convincingly demonstrated that T cell mediated immunopathology contributes to 
disease severity in pneumocystis infections 92. In a murine pneumocystis infection model, 
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presence vs. absence of antibiotics against pneumocystis (Trimethoprim/Sulfamethoxazole) 
did not impact on survival, while in vivo depletion of T cells reduced mortality 84. Activation-
induced T cell apoptosis is a well-studied tightly regulated process to avoid T cell over-
activity and immunopathology and to assure immune homeostasis 46. 
We thus aimed to experimentally study whether T cell intrinsic Sp110 might impact on 
activation-induced T cell apoptosis and subsequently T cell mediated immunopathology 
following pneumocystis infection. Therefore, we in vitro re-stimulated Sp110 competent vs. 
deficient human T cell blasts with either the phorbol-ester PMA (known to activate immune 
signalling pathways downstream of the T cell receptor 93), or induced apoptosis using an 
agonistic Fas (CD95)-specific antibody. Apoptosis was measured by AnnexinV staining and 
flow cytometric analysis. While both stimuli rapidly (within four hours) induced T cell 
apoptosis in Sp110 competent T cell blasts, a selective lack of apoptosis induction following 
PMA stimulation was repeatedly observed in T cell blasts derived from a VODI patient 
(patient nr. 1) (Figure 4a). While Fas-induced apoptosis was also slightly lower in T cell 
blasts derived from the VODI patient compared to T cell blasts from the two controls, the 
almost complete lack of PMA-induced apoptosis in Sp110 deficient T cell blasts was 
remarkable. Similarly, PMA failed to induce caspase-9 activation in T cell blasts derived from 
VODI patient nr. 1 while caspase-9 was activated in PMA re-stimulated Sp110 competent T 
cell blasts (Figure 4b). Thus, these results prompted us to study in more detail a potential 
role of Sp110 as a driver of activation-induced T cell death. 
PMA has several limitations as a small molecule compound that induces T cell intrinsic 
signalling resulting in activation induced T cell apoptosis. First, as shown in Figure 4c, PMA 
induced apoptosis is augmented in T cell blasts generated from memory T cells when 
compared to T cell blasts generated from flow-sorted naïve PBMC derived T cells. This 
increased activation induced T cell apoptosis in memory T cells was also observed for anti-
Fas treatment or TCR crosslinking with an agonistic anti-CD3 antibody (Figure 4c and data 
not shown). This finding is important to correct for when analysing human T cell blasts that 
consist of both naïve and memory T cell subpopulations. In addition, PMA failed to induce 
apoptosis in Jurkat T cells, even at concentrations that were 10-fold higher compared to PMA 
concentrations used to re-stimulate primary T cell blasts (Figure 4d). These results made 
PMA inappropriate as a compound to study activation induced apoptosis in SP110ko or 
SP110hi Jurkat T cells. In contrast, agonistic anti-Fas antibody induced apoptosis in Jurkat T 
cells comparably to primary T cell blasts (Figure 4d). While screening known inducers of T 
cell apoptosis, irradiation with UV-light was identified to induce dose-dependent apoptosis in 
both T cell blasts and Jurkat T cells (Figure 4e+f). In addition, flow-sorted naïve 
(CD3+CD27+CD45RO-) or memory (CD3+CD27-) PBMC derived T cells displayed similar 
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apoptosis following UV-light irradiation (Figure 4e). Thus, UV-light irradiation proved to be 
the most useful apoptosis-inducing stimulus for subsequent experiments in primary T cell 
blasts and Jurkat T cells with absent, normal or exceeding Sp110 levels.  
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Figure 4  
a+b) T cell blasts derived from a healthy control, a VODI patient (patient nr. 1) and a disease control 
patient (suffering from recurrent infections without evidence for immunodeficiency) were stimulated 
with either PMA or treated with agonistic anti-Fas antibody as indicated. a) Four hours later, T cell 
apoptosis was assessed by AnnexinV staining and flow cytometry. b) Activation of caspase-9 was 
measured by incubation of T cell blasts with fluorescently labelled caspase-9 inhibitor (FLICA) and 
flow cytometric analysis. c) T cell blasts generated from flow-sorted naïve (CD3+CD27+CD45RO-) or 
memory (CD3+CD27-) PBMC derived T cells were stimulated using the indicated compounds. 
Apoptosis was assessed by AnnexinV staining and flow cytometry four hours later. d) SP110wt Jurkat 
T cells were stimulated with the indicated concentrations of PMA or treated with agonistic anti-Fas 
antibody and apoptosis was quantified by AnnexinV staining and flow cytometric analysis four hours 
later. e) T cell blasts were generated from flow-sorted naïve (CD3+CD27+CD45RO-) vs. memory 
(CD3+CD27-) PBMC derived T cells and UV-light induced apoptosis was monitored using AnnexinV 
staining and flow cytometry. f) SP110wt Jurkat T cells were stimulated with the indicated intensities of 
UV-light. Four hours later, apoptosis was assessed using AnnexinV expression and flow cytometry. 
 
PMA induced apoptosis in primary T cell blasts via the JNK/c-Jun signalling pathway, as 
apoptosis was blockable by pre-incubation with the JNK-specific inhibitor SP600125 94 
(Figure 5a). SP600125 similarly blocked UV-light induced apoptosis in primary T cell blasts 
and in Jurkat T cells (Figure 5b). Flow cytometric analysis of c-Jun serine phosphorylation at 
position 73 using phospho-specific c-Jun monoclonal antibody 95 emphasized that SP600125 
pre-treatment indeed reduced c-Jun phosphorylation in primary T cell blasts and SP110wt 
Jurkat T cells (Figure 5c). PMA induced very low c-Jun phosphorylation in Jurkat T cells, 
probably explaining the lack of apoptosis induction in Jurkat T cells (data not shown). Thus, 
the JNK/c-Jun pathway is controlling PMA induced re-stimulation induced T cell apoptosis in 
primary T cell blasts and is orchestrating UV-light induced apoptosis in both primary T cell 
blasts and Jurkat T cells. 
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Figure 5 
a) Primary T cell blasts were pre-incubated with the inhibitor SP600125 for 30 minutes or left 
untreated. Cells were then stimulated with PMA and apoptosis was quantified four hours later using 
AnnexinV staining and flow cytometric analysis. b) T cell blasts generated from flow-sorted memory 
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(CD3+CD27-) PBMC derived T cells or SP110wt Jurkat T cells were irradiated with titrated intensities of 
UV-light. Apoptosis was assessed using AnnexinV staining and flow cytometric analysis four hours 
later. Pre-incubation with SP600125 for 30 minutes prior to UV-light irradiation served to block the 
JNK/c-Jun signaling pathway. c) Primary T cell blasts or SP110wt Jurkat T cells were pre-incubated 
with the c-Jun N-terminal kinase inhibitor SP600125 for 30 minutes and subsequently irradiated with 
titrated doses of UV-light. After one hour, the phosphorylation of c-Jun was assessed by phospho-flow 
cytometry. a-c) A representative histogram showing AnnexinV fluorescence is depicted in the left 
panel. Statistics were performed with an two-way ANOVA, ns = p>0,05; * = p<0,05; ** = p<0,005. 
Mean and standard deviation are depicted. 
 
Since UV-light irradiation was identified as the most advantageous in vitro stimulus to study 
re-stimulation induced apoptosis in Jurkat T cells with varying expression levels of Sp110, we 
next UV-light irradiated SP110wt vs. SP110hi Jurkat T cells and analyzed apoptosis induction. 
Treatment with agonistic anti-Fas antibody served as a control. While Fas-induced apoptosis 
was similar in both cell lines, SP110hi Jurkat T cells displayed exaggerated apoptosis 
following UV-light irradiation compared to SP110wt Jurkat T cells (Figure 6a). In a separate, 
confirmatory experiment, SP110ko, SP110wt and SP110hi Jurkat T cells were pre-incubated 
with the specific JNK inhibitor SP600125 or left untreated before irradiation with titrated 
doses of UV-light. Apoptosis induced by agonistic anti-Fas antibody served as a control. 
While T cell apoptosis was similar following anti-Fas treatment in all three cell lines, UV-light 
induced apoptosis correlated with Sp110 content, being highest in SP110hi and lowest in the 
SP110ko Jurkat T cells. UV-light induced, but not Fas-induced apoptosis was reduced by pre-
incubation with the JNK inhibitor SP600125 (Figure 6b). In summary, Sp110 expression 
levels in Jurkat T cells correlated with augmented apoptosis subsequent to activation of the 
JNK/c-Jun pathway. 
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Figure 6 
a) SP110wt and SP110hi Jurkat T cells were exposed to titrated intensities of UV-light or stimulated 
with an agonistic anti-Fas antibody. Four hours later, apoptosis was measured by flow cytometric 
quantification of AnnexinV binding. b) SP110ko, SP110wt and SP110hi Jurkat T cells were irradiated 
with titrated intensities of UV-light or incubated with an agonistic anti-Fas antibody. Four hours later, T 
cell apoptosis was monitored by AnnexinV staining and flow cytometric analysis. As a control, cells 
were incubated for 30 minutes with SP600125 to block JNK/c-Jun signalling prior to UV-light 
irradiation or Fas cross-linking (right panel) 
 
To confirm that the augmented UV-light induced apoptosis in SP110hi Jurkat T cells was 
indeed due to the heightened Sp110 expression, we established SP110 gene knockdown by 
transfection of SP110ko and SP110hi Jurkat T cells with SP110 specific siRNA. Transfection 
with non-specific siRNA served as a control (Figure 7a). Sp110 flow cytometric quantification 
24 hours following transfection with SP110 specific siRNA confirmed that Sp110 protein in 
SP110hi Jurkat T cells was almost completely knocked-down (Figure 7b). SP110ko or 
SP110hi Jurkat T cells were then UV-light irradiated and apoptosis was monitored four hours 
later. Treatment with agonistic anti-Fas antibody served as a control. Sp110 knockdown 
reduced UV-light induced apoptosis in SP110hi Jurkat T cells by 50%, while it did not affect 
UV-light induced apoptosis in SP110ko Jurkat T cells(Figure 7c). Fas-induced apoptosis was 
only slightly reduced by Sp110 knockdown in SP110hi cells (Figure 7c). In summary, these 
experiments reassured the Sp110 driven augmentation of JNK/c-Jun related T cell apoptosis. 
They also suggested that Sp110 impacted on apoptosis pathways that are not centrally 
involved during Fas-related apoptosis. 
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Figure 7 
a) A schematic graphical overview of the experiment is shown. b) SP110hi Jurkat T cells were 
transfected with SP110 specific (light grey histograms) or with non-specific siRNA (black histograms). 
24 hours later, Sp110 protein expression was determined by flow cytometry. c) SP110ko or SP110hi 
Jurkat T cells were transfected with siRNA as shown in a+b). 24 hours later, Jurkat T cells were UV-
light irradiated or incubated with agonistic anti-Fas antibody. Four hours later, apoptosis was 
quantified using AnnexinV staining and flow cytometric analysis. Representative histograms showing 
AnnexinV fluorescence in SP110hi Jurkat T cells are depicted together with a summary graph showing 
relative apoptosis reduction following SP110 siRNA transfection compared to transfection with non-
specific siRNA. 
 
3.2.1.1 T cell intrinsic Sp110 expression in T cells is regulated by 
interferon-α (IFN-I) 
 
The nuclear body protein Sp110 has been described to be upregulated upon IFN stimulation 
in HL-60 leukemia cell lines 10. To experimentally test whether also T cell intrinsic Sp110 
levels are modified by IFN, SP110wt Jurkats were stimulated with IFNα (IFN-I) for different 
time points. Incubation with IFN-I upregulated SP110 mRNA levels in SP110wt Jurkat T cells 
peaking at eight hours post-activation (Figure 8a). Sp110 protein upregulation peaked at 24 
hours after IFN I stimulation in SP110wt but not in SP110ko Jurkat T cells, confirming that the 
increased flow cytometric Sp110 signal was indeed Sp110 specific (Figure 8b). In addition 
we stimulated primary T cell blasts derived from a healthy individual or a VODI patient 
(patient nr.1) with IFN-I. 24 hours later, Sp110 flow cytometric analysis revealed IFN-I 
mediated Sp110 upregulation in Sp110 competent but not in Sp110 deficient T cell blasts 
(Figure 8b). We next assessed, with the help of phospho-specific monoclonal antibodies, the 
IFN-I-induced phosphorylation of STAT1 96 and 3 97 by flow cytometry. IFN-I induced rapid 
phosphorylation of STAT1 and STAT3 similarly in SP110ko and SP110wt Jurkats showing that 
early IFN-I signalling occurred independently of presence vs. absence of Sp110 (Figure 8c). 
STAT phosphorylation could be blocked by pre-incubation with the panSTAT inhibitor SH-4-
54 98 for 30 min prior to IFN-I stimulation (Figure 8c). Pre-incubation with the panSTAT 
inhibitor SH-4-54 also precluded IFN-I mediated Sp110 upregulation in SP110wt Jurkat T 
cells (Figure 8c). IFN-I activated SP110ko Jurkat T cells served as a staining control (Figure 
8c). Both, IFN-I driven STAT1 and STAT3 phosphorylation and IFN-I mediated upregulation 
of T cell intrinsic Sp110 protein levels could be similarly blocked by the JAK1/2 inhibitor 
Ruxolitinib 99 (Figure 8d). In summary, T cell intrinsic Sp110 levels, both in primary T cell 
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blasts and Jurkat T cells, are modified by IFN-I signals and are thus expected to be 
upregulated in inflamed tissues. 
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Figure 8 
a) SP110wt Jurkat T cells were stimulated with IFNα. At the indicated time points following IFNα 
stimulation, SP110 mRNA expression was quantified by real-time PCR. Sp110 transcript levels under 
non-stimulated conditions were set to 1. b) SP110ko and SP110wt Jurkat T cells were stimulated with 
IFNα (blue histograms) or were left non-stimulated (red histograms). In addition, primary PBMC 
derived T cell blasts from a healthy control and a VODI patient (patient nr.1) were stimulated with IFNα 
or left unstimulated. 24 hours later, Sp110 protein levels were measured by flow cytometry c) SP110ko 
and SP110wt Jurkat T cells were treated with the panSTAT inhibitor SH-4-54 for 30 min prior to 
stimulation with IFNα for one hour. The phosphorylation of STAT1 and STAT3 was analyzed by 
staining with phospho-STAT1 and phospho-STAT3-specific antibodies and flow cytometric analysis. In 
addition, SP110ko and SP110wt Jurkat T cells were incubated with the panSTAT inhibitor SH-4-54 
followed by IFNα stimulation. Sp110 expression was determined 24 hours later by flow cytometry. d) 
SP110wt Jurkat T cells were incubated with the JAK1/2 inhibitor Ruxolitinib for 30 min or left without 
pre-incubation prior to stimulation with IFNα. One hour later, phosphorylation of STAT1 or STAT3 was 
measured using respective phospho-specific antibodies and flow cytometric analysis. Aliquots of 
similarly IFNα stimulated, Ruxolitinib pre-incubated SP110wt Jurkat T cells were assessed 24 hours 
later for Sp110 protein expression by flow cytometry.  
 
3.2.1.2 IFN-I stimulation functionally converts SP110wt into SP110hi, 
apoptosis-prone T cells 
 
We hypothesized that IFN-I induced Sp110 upregulation might convert SP110wt Jurkat T cells 
functionally into SP110hi, apoptosis prone T cells. To experimentally study this, SP110wt 
Jurkat T cells were transfected with SP110 specific or non-specific siRNA and afterwards 
stimulated with IFN-I or left untreated for 24 hours. SP110wt Jurkat T cells were then 
irradiated with titrated doses of UV-light and apoptosis was assessed four hours later (see 
graphical overview of the experiment in Figure 9a). Stimulation with agonistic anti-Fas 
served as a control. Analysis of Sp110 protein expression by flow cytometry reassured that 
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transfection with SP110 specific siRNA completely blocked the IFN I driven Sp110 up-
regulation in SP110wt Jurkat T cells (Figure 9b). While Sp110 protein knockdown did not 
reduce UV-light induced apoptosis in SP110wt Jurkat T cells, a knockdown of Sp110 protein 
in IFN-I stimulated SP110wt Jurkat T cells reduced UV-light triggered apoptosis (Figure 9c). 
In other words, approximately 40% of UV-light (100 J/m2) induced apoptosis in IFN-I 
activated SP110wt Jurkat T cells occurred Sp110 dependently. These results were 
comparable to the Sp110 augmented apoptosis measured in SP110hi Jurkat T cells following 
UV-light irradiation (Figure 7). Using the same experimental approach in primary human T 
cell blasts confirmed that Sp110 protein knockdown reduced UV-light induced apoptosis in 
IFN-I stimulated, but only minimally in non-activated T cell blasts. In contrast, only a small 
contribution of Sp110 to Fas-related apoptosis was observed (Figure 9d).  
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Figure 9 
a) A schematic graphical overview of the experimental setup is depicted. a-c) SP110wt Jurkat T cells 
were transfected with non-specific or SP110 specific siRNA followed by stimulation with IFNα. Non-
stimulated conditions served as a control. b) 24 hours later, Sp110 protein expression in T cells was 
quantified by flow cytometry. a-c) 24 hours following siRNA transfection, cells were irradiated with the 
indicated intensities of UV-light and apoptosis was measured four hours later by AnnexinV staining 
and flow cytometric analysis. The reduction of apoptosis in the absence vs. presence of Sp110 is 
depicted. d) Primary T cell blasts derived from healthy individuals were transfected with non-specific 
or SP110 specific siRNA followed by stimulation with IFNα. Non-stimulated conditions served as a 
control. 24 hours later, T cell blasts were irradiated by the indicated doses of UV-light or incubated 
with agonistic anti-Fas antibody. Four hours later, apoptosis was measured by AnnexinV staining and 
flow cytometric analysis. The reduction of apoptosis in the absence vs. presence of Sp110 is depicted. 
Statistics were done with an two-way ANOVA, ns = p>0,05; * = p<0,05; ** = p<0,005. Mean and 
standard deviation are depicted. 
 
3.2.1.3 Analysis of molecular mechanisms driving Sp110 dependent T 
cell apoptosis 
 
Our previous results have shown that UV-light induced apoptosis both in primary T cell blasts 
and Jurkat T cells occurs JNK/c-Jun dependently (Figure 5). For this reason we next 
analyzed whether T cell intrinsic Sp110 levels impacted on phosphorylation of c-Jun 
following UV-light exposure. SP110wt and SP110hi Jurkat T cells were transfected with SP110 
specific or non-specific siRNA and rested for 24 hours. Subsequently, Jurkat T cells were 
UV-light irradiated and one hour later the phosphorylation of c-Jun was assessed by 
phospho-flow cytometry. Phosphorylation of c-Jun occurred within one hour following UV-
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light irradiation but was independently of Sp110 protein levels (Figure 10a). Thus, early UV-
light induced T cell intrinsic signaling occurred independently of Sp110 protein levels. Next, 
we experimentally assessed whether UV-light induced apoptosis, which correlated with 
Sp110 expression levels, was affecting caspase-9 activation indicating activation of the 
intrinsic apoptosis pathway 100. SP110ko, SP110wt and SP110hi Jurkat T cells were irradiated 
with UV-light and cell lysates were preserved. Immunoblot analysis using a caspase-9 
specific antibody demonstrated two proteolytically cleaved, caspase-9 bands, representing 
activated caspase-9 101 at around 35-37 kDa besides non-activated full-length caspase-9 (50 
kDa). Lysates generated from UV irradiated SP110hi Jurkat T cells revealed heightened 
caspase-9 activation (Figure 10b). Thus, UV-light irradiation induced T cell intrinsic, Sp110 
augmented apoptosis correlating with enhanced activation of the intrinsic apoptosis pathway. 
Since intrinsic apoptosis is controlled by expression levels of proapoptotic BH3-only proteins 
such as NOXA, PUMA and BIM 61 64, we next investigated transcriptional levels of the 
corresponding genes. SP110ko, SP110wt and SP110hi Jurkat T cells were irradiated with UV-
light. Four hours after UV-light irradiation of SP110ko, SP110wt and SP110hi Jurkat T cells, 
cDNA was generated and the levels of PUMA, NOXA and BIM mRNA were quantified by 
real-time PCR. While UV-light induced NOXA and BIM expression did not correlate with 
Sp110 expression levels, we found a two-fold induction of PUMA mRNA in SP110hi but not in 
SP110ko and SP110wt Jurkat T cells following UV-light irradiation (Figure 10c). These results 
identified PUMA as a potential Sp110 regulated gene. 
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Figure 10 
a) SP110wt and SP110hi Jurkat T cells were transfected with SP110 specific or non-specific siRNA. 24 
hours later the cells were stimulated by UV-light irradiation. One hour later, phosphorylation of c-Jun 
was determined by staining with a phospho-specific anti-c-Jun antibody and flow cytometric analysis. 
b) SP110ko, SP110wt and SP110hi Jurkat T cells were irradiated with 100 J/m2 UV-light. Four hours 
later, cellular lysates were analyzed by western blot for expression of full-length or activated, cleaved 
caspase-9 expression. A ratio of the signal intensities of cleaved caspase-9 to full-length caspase-9 
was calculated and is depicted (left panel). The ratio of the signal intensities of cleaved caspase-9 
over full-length caspase-9 in non-stimulated SP110ko Jurkat T cells was arbitrarily set to 1. c) SP110ko, 
SP110wt and SP110hi Jurkat T cells were irradiated with UV-light (100 J/m2). Four hours later, cDNA 
was generated and the expression of PUMA, NOXA or BIM was quantified by real-time PCR. The 
mRNA expression was normalized to mRNA levels of the indicated gene measured in the respective 
Jurkat T cells in the absence of UV-light stimulation. 
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3.2.1.4 Sp110 driven T cell apoptosis does not require expression of the 
full bromodomain 
 
The bromodomain of Sp110 is thought to play an important role for its transcriptional function 
22. To experimentally test whether expression of the full-length Sp110 isoform encoding a 
complete bromodomain is required for Sp110 augmented T cell apoptosis, two different 
Jurkat T cell lines overexpressing the truncated SP110 isoform A were generated by lentiviral 
transduction. Both SP110iso-A Jurkat T cell lines overexpressed SP110 four-fold as measured 
by real-time PCR compared to SP110wt Jurkat T cells (data not shown). Endpoint PCR 
analysis using primer amplifying all four SP110 isoforms (see Figure 1c) revealed that 
SP110wt Jurkat T cells primarily expressed the full-length SP110 isoform C (Iso C) whereas 
the SP110iso-A Jurkat T cell lines expressed particularly the truncated SP110 isoform A (Iso A) 
(Figure 11a). When the different Jurkat T cell lines were irradiated with titrated amounts of 
UV-light, both SP110hi and SP110iso-A Jurkat T cell lines displayed augmented apoptosis 
induction compared to SP110wt Jurkat T cells. Fas-induced apoptosis was similar in all tested 
Jurkat T cell lines (Figure 11b). In a separate set of experiments, we confirmed that UV-light 
induced apoptosis, also in SP110iso-A Jurkat T cells, occurred via the JNK/c-Jun pathway, as 
it was blockable by pre-incubation with the JNK specific inhibitor SP600125 (Figure 11c). In 
summary, these data suggested that Sp110 driven JNK/c-Jun dependent apoptosis did not 
require expression of a full bromodomain. 
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Figure 11 
a) cDNA of the indicated Jurkat T cell lines was generated and endpoint PCR specific for the indicated 
SP110 isoforms was performed. Specific bands were visualized following agarose gel separation. b) 
SP110wt and two SP110iso-A Jurkat T cell lines were irradiated with titrated doses of UV-light or 
stimulated with an agonistic anti-Fas antibody. Four hours later, apoptosis was assessed by AnnexinV 
staining and flow cytometric analysis. c) SP110wt and two SP110iso-A Jurkat T cell lines were irradiated 
with titrated doses of UV-light in the absence vs. presence of the JNK/c-Jun specific inhibitor 
SP600125. Four hours later, Jurkat T cell apoptosis was measured by AnnexinV staining and flow 
cytometric analysis.  
 
3.2.2 T cell intrinsic IFN-γ production is regulated by Sp110 expression 
 
While impaired activation induced apoptosis may support T cell mediated immunopathology, 
uncontrolled excess T cell-intrinsic cytokine production has also been linked to 
immunopathological disease, exemplarily shown in hemophagocytic lymphohistiocytosis 
(HLH) 102. We therefore experimentally addressed the question whether presence vs. 
absence of Sp110 in T cells might regulate production of T cell specific cytokines. SP110ko, 
SP110wt and SP110hi Jurkat T cells were stimulated with UV-light and upregulation of IFNγ 
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mRNA was assessed by real-time PCR four hours later. IFNγ mRNA was 30-fold increased 
following UV-light stimulation in SP110ko Jurkat T cells, while upregulation was 4 - 6-fold 
lower in Sp110 competent Jurkat T cells. In contrast, TNFα mRNA was only minimally 
induced following UV-light irradiation in all Jurkat T cell lines tested (Figure 12a). To confirm 
that absence of Sp110 induced excess T cell intrinsic IFNγ formation, we transfected 
SP110wt Jurkat T cells with SP110 vs. non-specific siRNA followed by stimulation with IFN-I 
for 24 hours. Afterwards cells were UV-light irradiated and IFNγ mRNA levels were quantified 
by real-time PCR four hours later. Sp110 knockdown was associated with excess UV-light 
driven IFNγ mRNA levels, particularly in IFN-I activated SP110wt Jurkat T cells (Figure 12b).  
 
 
 
 
Figure 12 
a) SP110ko, SP110wt and SP110hi Jurkat T cells were irradiated with UV-light (100J/m2). Four hours 
later, cDNA was generated and IFNγ or TNFα transcripts were quantified by real-time PCR. The fold-
increase compared transcript levels measured in non-stimulated cells (set to 1) is depicted. b) SP110wt 
Jurkat T cells were transfected with SP110 specific or non-specific siRNA as indicated, followed by 
stimulation with IFN-I. Non-stimulated conditions served as a control. 24 hours later, Jurkat T cells 
were irradiated with UV-light (100J/m2) or left non-irradiated and IFNγ mRNA was assessed by real-
time PCR four hours later. IFNγ transcript levels are depicted relative to levels measured in non-
irradiated conditions (set to 1).  
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4 Discussion 
4.1 Flow-cytometric detection of T cell intrinsic Sp110 to screen for 
veno-occlusive disease with immunodeficiency (VODI) and 
other potential clinical applications 
 
The diagnosis of veno-occlusive disease with immunodeficiency has been challenging, as it 
was mainly based on genetic detection of rare SP110 mutations already known to cause 
VODI. The testing of functional consequences of novel SP110 mutations has until now been 
virtually impossible since no functional Sp110 dependent immune-assays have been 
described. As part of my PhD thesis we have established the flow-cytometric detection of 
Sp110 protein quantity in peripheral blood derived human T cells. This novel flow-cytometry 
based method has been recently published by Marquardsen and Baldin et al in the Journal of 
Clinical Immunology allowing to rapidly screen patients for potential VODI 88. A not yet 
published modification of this diagnostic test is to apply Sp110 flow-cytometric quantification 
in PBMC derived T cells following in vitro IFN-I stimulation vs. non-stimulated conditions. As 
IFN-I treatment increases T cell intrinsic Sp110 expression, the advantage of this 
modification is that the Sp110 signal difference between Sp110 competent vs. deficient T 
cells is increasing, thereby augmenting the sensitivity of the diagnostic test. In addition, in 
vitro IFN-I stimulation prior to Sp110 flow-cytometric analysis allows functional testing of 
normal Sp110 regulation by IFN-I. This would allow to identify Sp110 deficient patients with 
e.g. mutations in the SP110 promotor that would not be diagnosed when performing exon-
based Sanger sequencing or whole exome sequencing. 
Besides VODI, the flow cytometric analysis of Sp110 allows to functionally characterize 
single nucleotide variants (SNP) in the SP110 gene and their respective impact on Sp110 
expression. It also remains to be tested whether specific SP110 SNP associate with T cell 
apoptosis or IFNγ production. 
As Sp110 is an IFN-stimulated protein, the flow-cytometric quantification of Sp110 could also 
have a diagnostic role to detect diseases associated with increased IFN-I responses. 
Interferonopathies are monogenic PID due to gain of function mutations in genes regulating 
IFN-I formation 103. These diseases often manifest as autoimmune diseases 42. In addition, 
polygenetic diseases such as systemic lupus erythematosus (SLE) or chronic virus infections 
are linked to enhanced IFN production 42 104. The detection of exaggerated IFN-I production 
by ELISA has been proven difficult 105. Monitoring Sp110 levels by flow-cytometry in 
peripheral blood derived cells may be used as a biomarker of the clinical activity of these 
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diseases and their response to immune-modulating treatment. 
 
4.2 Sp110 as a regulator of JNK/c-Jun dependent T cell apoptosis 
 
Overexpression of T cell intrinsic Sp110 augmented UV-light induced apoptosis both in 
primary human T cell blasts and Jurkat T cells. Since phosphorylation of c-Jun as assessed 
by flow-cytometry occurred independently of Sp110 protein levels, we hypothesize that 
Sp110 may alter c-Jun dependent gene-regulation in the nucleus. Sp110 is guided to the 
nucleus via its NLS whereas c-Jun is transported to the nucleus via a specific nuclear import 
receptor 10 106. c-Jun phosphorylation is not required for nuclear import 107. Indeed, c-Jun has 
been demonstrated to associate with PML, which, like Sp110, is member of the family of 
PML nuclear body proteins 108. The association of PML with c-Jun requires c-Jun 
phosphorylation 108. It thus seems reasonable to hypothesize that phosphorylated c-Jun 
directly interacts with Sp110 and as a consequence of this induces altered gene 
transcription. We are currently experimentally testing whether Sp110 and p-c-Jun co-localize 
following UV-light irradiation using immunofluorescence imaging and immunoprecipitation 
techniques. 
Although we have mainly studied UV-light induced T cell apoptosis, we believe that our 
results are relevant for T cell apoptosis induced via T cell receptor (TCR) crosslinking. In 
support of this, T cells from JNK1-deficient mice have been demonstrated to display reduced 
activation induced T cell apoptosis following TCR ligation 109. In addition, activation induced T 
cell apoptosis of melanoma-specific or influenza-specific T cells upon interaction with 
cognate peptide has been demonstrated to occur JNK dependently 110 111 112. We have 
shown that both PMA stimulation and TCR cross-linking by agonistic anti-CD3 antibody 
induced phosphorylation of c-Jun, with similar kinetics compared to UV-light irradiation (data 
not shown). It is noteworthy, that irradiation activates similar signalling pathways as TCR 
cross-linking 113. Besides the rather selective activation of the JNK/c-Jun signalling pathway 
following UV-light irradiation, TCR cross-linking will simultaneously activate a broader range 
of signalling pathways, including the NF-κB pathway, which might impact on c-Jun 
dependent apoptosis 114. 
Some proapoptotic BH-3 only proteins such as NOXA, PUMA and BIM are transcriptionally 
regulated and represent thus interesting candidates as potentially Sp110 regulated proteins 
115. Together with NOXA, PUMA favours MOMP by activating the proapoptotic BCL-2 family 
members BAK and BAX 63 65. Our results demonstrate that upon UV-light irradiation of Jurkat 
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T cells, PUMA mRNA increase was highest in Jurkat T cells overexpressing Sp110. In 
contrast, no such Sp110 dependent effect was observed for NOXA or BIM mRNA 
expression. Still, this association has not yet been shown to be causal for the increased 
Sp110 dependent apoptosis augmentation. Experiments are planned to analyse whether 
augmented apoptosis induced by Sp110 overexpression is reduced by siRNA mediated 
knock down of PUMA expression. A more unbiased approach would be to transfect SP110hi 
Jurkat T cells or IFN-stimulated primary human T cell blasts with SP110 specific siRNA and 
compare the UV-light induced transcriptome with T cells transfected with non-specific siRNA. 
In addition, chromatin immunoprecipitation DNA-sequencing (ChIP-seq) experiments will 
help to define potential Sp110 regulated genes.  
 
4.3 Regulation of UV-light induced T cell apoptosis by different 
Sp110 isoforms 
 
The nuclear body protein Sp110 contains different functional domains, including a 
bromodomain at the C-terminus of the protein (also see Figure 1b) 10. This domain is 
thought to be important for the transcriptional activity of Sp110 22. A very recent study from 
Leu et al showed that different Sp110 isoforms have specific functions regarding the 
regulation of gene expression. The middle region and the C-terminal part of SP110 are 
regulating the cellular localization of the protein. Besides the NLS, this study reported that 
the Sp110 SAND and bromodomain are essential for correct nuclear targeting 23. Our results 
showed that all four main SP110 isoforms are expressed in primary human T cell blasts from 
healthy individuals. We have not yet assessed the T cell intrinsic expression compartment of 
the different Sp110 isoforms, but this could be achieved by overexpression of selected 
Sp110 isoforms in SP110ko Jurkat T cells followed by immunofluorescence microscopy or 
western blot analysis of lysates of enriched subcellular compartments. 
However, we have experimentally demonstrated that overexpression of SP110 isoform A, 
lacking parts of the bromodomain, similar to overexpression of the full length isoform C, 
augmented UV-light induced, JNK/c-Jun dependent apoptosis. This suggests that the 
missing bromodomain part in isoform A is dispensable for Sp110 augmented apoptosis. 
Similar functional analyses in Jurkat T cells overexpressing the other Sp110 isoforms will 
allow to better defining required protein domains for the apoptosis-enhancing functions of 
Sp110.  
 
Discussion  47 
 
4.4 The role of IFN-I in Sp110 augmented apoptosis, 
immunopathology and immune dysregulation 
 
Sp110 is an interferon stimulated protein 10. Our results imply that a certain level of Sp110 
protein is required to mediate Sp110 augmented T cell apoptosis. This critical threshold of 
Sp110 expression is higher compared to basal levels found at steady state in both primary 
human T cell blasts and Jurkat T cells but is reached in both cell types following IFN-I 
stimulation in vitro. In other words, IFN-I increases Sp110 to levels where Sp110 dependent 
apoptosis augmentation is observed. Bringing these findings into a clinical context it is likely 
that Sp110 augmented T cell apoptosis occurs primarily in inflamed tissues where IFN-I 
production mainly occurs, such as e.g. in the lung during pneumocystis infection. The 
experimental evidence that Sp110 does not control activation induced T cell apoptosis at 
steady state would easily explain why Sp110 deficiency does not lead to altered T cell 
homeostasis in the absence of infection. The immune-biologic correlate of this are the normal 
numbers of T cells and the absence of lymphoproliferation (splenomegaly and/or 
lymphadenopathy) in patients with VODI 6. In contrast, during pneumocystis infection of 
immunologically healthy individuals, local IFN-I levels would rise and enhance Sp110 levels 
to a threshold where activation induced T cell apoptosis is augmented, thus prohibiting 
immunopathological lung damage. This proposed mechanism is not specific for 
pneumocystis and would apply similarly for other infections that are linked to 
immunopathology. Notably, T cell mediated immunopathology has been postulated in murine 
and human CMV infections which are known to induce life-threatening disease in VODI 
patients 116 117 118 86. Besides its essential role in the pathogenesis of VODI, Sp110 
augmented apoptosis might also play a role in other diseases that are associated with 
enhanced IFN-I or ISG-signature. These consist of the rare above-mentioned 
interferonopathies leading to enhanced or uncontrolled ISG activation due to monogenic 
mutations in genes controlling IFN-I formation 42. More frequent, polygenic systemic 
autoimmune diseases such as SLE or chronic viral infections such as HIV are linked to 
exaggerated IFN-I production 119 120. These states of IFN-I overproduction, based on our 
proposed mechanism, would be associated with enhanced T cell apoptosis. Indeed, T cell 
lymphopenia is a typical hallmark of both SLE and HIV 121 91. 
Further studies are planned to experimentally test the hypothesis that in these autoimmune 
or chronic virus replication-associated diseases, IFN-I driven Sp110 overexpression would 
drive T cell apoptosis and thus contribute to T cell lymphopenia.  
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4.5 Sp110 dependent regulation of T cell intrinsic IFN-γ production 
 
IFNγ is a key effector cytokine produced by activated T cells 122. It is essential for the control 
of intracellular pathogens such as mycobacteria 123. On the other hand, uncontrolled or 
excess IFNγ production is known to be the cause for immunopathology. This has been 
exemplarily shown in HLH where uncontrolled IFNγ causes immunopathologic disease that is 
associated with high mortality 102. In fact, biologics targeting IFNγ are currently used in 
clinical trials to treat immunopathologic diseases 124. T cell-dependent immunopathology is 
also a hallmark of pneumocystis pneumonia 125 126. The mechanisms how IFNγ enhances 
immunopathology are pleiotropic including, amongst others, macrophage activation, 
upregulation of MHC molecules and thus augmentation of antigen presentation and 
increased attraction of cytotoxic CD8+ T cells into the inflamed area which further augments 
IFN-γ formation 127 128 129.  
Our experiments demonstrate that absence of Sp110 expression was associated with 
augmented IFNγ mRNA levels following UV irradiation of Jurkat T cells. If control 
experiments confirm this regulatory function of Sp110 also in primary human T cells, we have 
identified a previously unknown immune-regulatory function of Sp110. 
In VODI patients, both, the identified Sp110 dependent effect on T cell apoptosis on one 
hand and the regulation of IFNγ production on the other hand are altered. During 
pneumocystis infection, this would result in activated T cells that displaying impaired 
activation-induced apoptosis in inflamed tissue while secreting uncontrolled amounts of IFNγ. 
This might explain the special susceptibility to severe pneumocystis infections in VODI 
patients. A graphical summary assembling all identified Sp110 dependent T cell intrinsic 
functions and their relation to T cell immunopathology during pneumocystis infection are 
depicted in Figure 13. 
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Figure 13 Lung picture was copied from https://smart.servier.com 
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